Stefan Gruenwald
Directeur/Membre du Conseil chez ONCOLOGY PHARMA INC.
Profil
Stefan Gruenwald is the founder of Orbigen, Inc. (founded in 2000) and Diagnomics, Inc. (founded in 2011, where he also holds the title of President & Director).
He is also the founder of Genautica.
Currently, he holds the position of Independent Director at Oncology Pharma, Inc. (since 2019).
Previously, he held the position of Vice President-Research & Development at Becton, Dickinson & Co. (from 1997 to 2000) and the title of Chief Scientific Officer at Quadraspec, Inc. He also held the title of Principal at PharMingen.
Dr. Gruenwald obtained a doctorate degree from Johann Wolfgang Goethe-Universität Frankfurt am Main.
Postes actifs de Stefan Gruenwald
| Sociétés | Poste | Début |
|---|---|---|
| ONCOLOGY PHARMA INC. | Directeur/Membre du Conseil | 08/10/2019 |
Diagnomics, Inc.
 Diagnomics, Inc. Miscellaneous Commercial ServicesCommercial Services Diagnomics, Inc. engages in the research and development of personalized advanced healthcare services. It offers consumer genomics solutions, analysis platform, clinical and translational research, assay development support, and bioinformatics services. The company was founded by Min Seob Lee, Stefan Gruenwald, and Dan Scholefield in 2011 and is headquartered in San Diego, CA. | Fondateur | 01/01/2011 |
| Genautica | Directeur Général | - |
Anciens postes connus de Stefan Gruenwald
| Sociétés | Poste | Fin |
|---|---|---|
Quadraspec, Inc.
 Quadraspec, Inc. Medical SpecialtiesHealth Technology Quadraspec, Inc. is a diagnostic company engaged in the development of in-vitro diagnostic products for the laboratory, clinical, research and life sciences markets. Their products are used in veterinary for canine heartworm, by biotechnology companies for assay development, biomarker identification, and patient screening during pre-clinical and clinical development and in clinical diagnostics. It developed a direct detection technology which eliminates the usage of secondary and labeled reagents. The company’s proprietary Spinning Disc Interferometry (SDI) Detection technology platform detects and quantifies more than 1,000 unique antigens, biomarkers, or other molecular species on a single array providing a reagent-free detection technology. Its dual channel detector, Inspira Reader features reagent-free detection and orthogonal detection method for quantification of molecular assays. The company was founded in 2004 and is headquartered in West Lafayette, Indiana. | Directeur Technique/Scientifique/R&D | 23/07/2010 |
| BECTON, DICKINSON AND COMPANY | Directeur Technique/Scientifique/R&D | 01/01/2000 |
PharMingen
 PharMingen BiotechnologyHealth Technology Part of Becton, Dickinson & Co., PharMingen is a company that manufactures antibodies and reagents for biological research. The company is based in San Diego, CA. PharMingen was acquired by Becton, Dickinson & Co. on May 19, 1997. | Corporate Officer/Principal | 01/01/1997 |
| Orbigen, Inc. | Fondateur | - |
Formation de Stefan Gruenwald
| Johann Wolfgang Goethe-Universität Frankfurt am Main | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BECTON, DICKINSON AND COMPANY | Health Technology |
| ONCOLOGY PHARMA INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Quadraspec, Inc.
Quadraspec, Inc. Medical SpecialtiesHealth Technology Quadraspec, Inc. is a diagnostic company engaged in the development of in-vitro diagnostic products for the laboratory, clinical, research and life sciences markets. Their products are used in veterinary for canine heartworm, by biotechnology companies for assay development, biomarker identification, and patient screening during pre-clinical and clinical development and in clinical diagnostics. It developed a direct detection technology which eliminates the usage of secondary and labeled reagents. The company’s proprietary Spinning Disc Interferometry (SDI) Detection technology platform detects and quantifies more than 1,000 unique antigens, biomarkers, or other molecular species on a single array providing a reagent-free detection technology. Its dual channel detector, Inspira Reader features reagent-free detection and orthogonal detection method for quantification of molecular assays. The company was founded in 2004 and is headquartered in West Lafayette, Indiana. | Health Technology |
PharMingen
PharMingen BiotechnologyHealth Technology Part of Becton, Dickinson & Co., PharMingen is a company that manufactures antibodies and reagents for biological research. The company is based in San Diego, CA. PharMingen was acquired by Becton, Dickinson & Co. on May 19, 1997. | Health Technology |
| Orbigen, Inc. | |
Diagnomics, Inc.
Diagnomics, Inc. Miscellaneous Commercial ServicesCommercial Services Diagnomics, Inc. engages in the research and development of personalized advanced healthcare services. It offers consumer genomics solutions, analysis platform, clinical and translational research, assay development support, and bioinformatics services. The company was founded by Min Seob Lee, Stefan Gruenwald, and Dan Scholefield in 2011 and is headquartered in San Diego, CA. | Commercial Services |
| Genautica |
